Skip to main content
. Author manuscript; available in PMC: 2013 Nov 1.
Published in final edited form as: Bone. 2012 Aug 14;51(5):835–846. doi: 10.1016/j.bone.2012.08.111

Figure 2.

Figure 2

Bioassay in the prevention-HT paradigm in WT, AR2.3-tg and AR3.6-tg male mice using androgen-responsive tissue weight after ORX and with DHT treatment for 6 weeks. A. SV weight during HT intervention as prevention treatment. (n = 10–32). B. LABC muscle weight during HT. (n = 10–26). All data expressed as mean ± SEM. Significance was assessed by one-way ANOVA with Newman-Keuls Multiple Comparison post-hoc test or two-sided student's t-test. *** p < 0.001 vs. sham controls; ### p < 0.001 vs. ORX.